Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug
A startup founded by biotech A-listers has scored $22 million in a Series B round to help develop its NASH drug. The company, called Metacrine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
